Substandard Capsule Issues Hasten China’s Drug Quality Efforts
This article was originally published in PharmAsia News
Executive Summary
The recent substandard capsule scandal is likely to accelerate China’s efforts to switch government procurements’ focus from prices to quality, a securities firm said.